CAM
REGN icon

Cresset Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Cresset Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75M Buy
2,803
+266
+10% +$181K 0.01% 712
2026
Q1 		$1.96M Sell
2,537
-318
-11% -$243K 0.01% 562
2025
Q4 		$2.2M Buy
2,855
+3
+0.1% +$2.04K 0.01% 538
2025
Q3 		$1.6M Buy
2,852
+48
+2% +$27.1K 0.01% 609
2025
Q2 		$1.47M Sell
2,804
-1,339
-32% -$747K 0.01% 577
2025
Q1 		$2.63M Sell
4,143
-128
-3% -$88K 0.01% 464
2024
Q4 		$3.04M Sell
4,271
-6,164
-59% -$5.17M 0.01% 445
2024
Q3 		$11M Buy
10,435
+198
+2% +$220K 0.04% 283
2024
Q2 		$10.8M Buy
10,237
+740
+8% +$717K 0.05% 262
2024
Q1 		$9.14M Buy
9,497
+26
+0.3% +$24.7K 0.04% 270
2023
Q4 		$8.32M Buy
9,471
+607
+7% +$500K 0.05% 242
2023
Q3 		$7.29M Buy
8,864
+43
+0.5% +$33.8K 0.03% 258
2023
Q2 		$6.34M Buy
8,821
+6,874
+353% +$5.3M 0.01% 360
2023
Q1 		$1.6M Buy
1,947
+73
+4% +$55.1K 0.03% 260
2022
Q4 		$1.27M Sell
1,874
-133
-7% -$98.1K 0.02% 267
2022
Q3 		$1.38M Sell
2,007
-29
-1% -$18.3K 0.02% 280
2022
Q2 		$1.18M Buy
2,036
+597
+41% +$388K 0.01% 342
2022
Q1 		$1.01M Sell
1,439
-203
-12% -$128K 0.01% 405
2021
Q4 		$1.04M Buy
1,642
+208
+15% +$128K 0.01% 445
2021
Q3 		$868K Buy
1,434
+90
+7% +$55.9K 0.01% 438
2021
Q2 		$751K Sell
1,344
-651
-33% -$330K 0.01% 432
2021
Q1 		$943K Buy
1,995
+744
+59% +$362K 0.01% 321
2020
Q4 		$604K Sell
1,251
-149
-11% -$80.4K 0.01% 349
2020
Q3 		$784K Buy
1,400
+49
+4% +$29.7K 0.01% 269
2020
Q2 		$843K Buy
1,351
+392
+41% +$223K 0.02% 238
2020
Q1 		$370K Buy
959
+400
+72% +$165K 0.01% 342
2019
Q4 		$210K Buy
+559
New +$188K 0.01% 547
2019
Q2 		– Sell
-495
Closed -$203K – 1405
2019
Q1 		$203K Buy
495
+72
+17% +$29.6K 0.01% 372
2018
Q4 		$158K Buy
+423
New +$155K 0.01% 253

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cresset Asset Management's REGN Position: Q2 2026 in Review

Cresset Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 10% in Q2 2026, buying an estimated $181K and bringing the position to 2,803 shares worth $1.75M. The position accounts for 0.01% of the portfolio, ranked #712.

Cresset Asset Management first reported a position in REGN in Q4 2018 and has held it in 29 quarters since. The position peaked at $11M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Cresset Asset Management held 2,803 shares of Regeneron Pharmaceuticals worth $1.75M as of Q2 2026.
  • Cresset Asset Management bought 266 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $181K.
  • Regeneron Pharmaceuticals made up 0.01% of Cresset Asset Management's portfolio in Q2 2026, its #712 holding.
  • Cresset Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 29 quarters since.
  • Cresset Asset Management's Regeneron Pharmaceuticals position peaked at $11M in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.